2025 GIGA Annual Report | 53 SEVERAL EXCITING DEVELOPMENTS ARE ALSO UNDERWAY ACROSS PLATFORMS In Proteomics, progress is accelerating: They fine-tuned workflows on the timsTOF SCP (acquired in 2023 with support from the Foundation Against Cancer), successfully performing differential proteomic analysis with as few as 250 FACS-sorted cells. Immunopeptidomics is now possible using the DDApasef acquisition mode. Sweat sample analysis has been validated on over 150 specimens. Sample prep has been fully automated using the Formulatrix Mantis. In Cell Imaging, advances in FLIM and TRIF-HILO techniques are enhancing our ability to capture subtle cellular dynamics. In Human In Vivo Imaging, the new Brain-to-Body MR Imaging project is now underway. The Viral Vector facility works on the development of method for production of AAV bearing nanobodies at their surface for better specific targeting. In Genome Editing, CRISPR-Cas9 technology has enabled the generation of new knock-in mouse lines. Meanwhile, the Animal Facility is pushing innovation further: A combined ear punch technique for genotyping and identification is now standard practice. Non-surgical embryo transfer (NSET) protocols are in development with the Gene editing Platform. Work has also begun on sonic stimulation methods to induce pseudopregnancy in females, replacing the need for male vasectomy surgeries.
RkJQdWJsaXNoZXIy MTk1ODY=